Update to our tumour BRCA testing service:

We are happy to announce that AstraZeneca and MSD will continuing to provide funding for tumour BRCA testing via the BRCAct service through our partner laboratories. Our aim is to support the NHS in minimising any interruption to patient care during these unprecedented times.

As part of this, we have amended the test request forms to make it clear that cytology samples can be used as a sample source for testing. This provides an alternative source of sample where there are issues with obtaining tumour tissue directly. Please check the individual test request forms for specifics around the preparation of these samples.

Finally, we have made the decision to expand access to the service to include all adult patients with relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer irrespective if they have had previous germline BRCA testing or not.

Why to BRCA test in ovarian cancer5-15

Watch Professor Gourley and Professor Edmondson discuss the importance of tumour BRCA testing at diagnosis

Lynparza prescribing information can be found here

About tumour BRCA testing

Unlike germline testing, tumour testing can identify both germline and somatic mutations

  • Tumour BRCA test all your newly diagnosed advanced ovarian cancer patients to identify those who may benefit from Lynparza in the first-line.1,19
  • Unlike germline testing, tumour testing can identify both germline and somatic BRCAm.1 Subsequent germline testing can determine whether there are any familial impliations for the patient’s family.19
  • In a woman diagnosed with ovarian cancer, any BRCA mutation(s) will be present in the tumour cells, whether the mutation is germline or somatic.20
  • In contrast to a blood test, this means that tumour BRCA testing enables the detection of both types of mutations. Compared with blood-based testing, tumour testing can help to identify around 50% more of the women with ovarian cancer who have a BRCA mutation.21